Therapeutic Vision has developed Kinostat for treating vision loss in diabetic dogs. In an FDA trial, Kinostat treated dogs were 85% and 84% less likely to develop cataracts and dry eye, respectively vs placebo. Compassionate use shows it safely preserved vision for 8 years. We have provisional approval to market Kinostat pending CMC submission and a bridging study. This drug class also beneficially reduces dry eye and promotes corneal healing in diabetic humans, safely allowing LASIK surgery.
Connect with Therapeutic Vision, Inc.